Fresenius Medcl Company Profile
✉ Email this page to a colleague
What is the competitive landscape for FRESENIUS MEDCL, and when can generic versions of FRESENIUS MEDCL drugs launch?
FRESENIUS MEDCL has nine approved drugs.
There are three US patents protecting FRESENIUS MEDCL drugs.
There are twenty-one patent family members on FRESENIUS MEDCL drugs in sixteen countries and ninety-three supplementary protection certificates in thirteen countries.
Summary for Fresenius Medcl
International Patents: | 21 |
US Patents: | 3 |
Tradenames: | 22 |
Ingredients: | 5 |
NDAs: | 9 |
Drugs and US Patents for Fresenius Medcl
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fresenius Medcl | DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER | calcium chloride; dextrose; magnesium chloride; sodium chloride; sodium lactate | SOLUTION;INTRAPERITONEAL | 018379-007 | Jun 24, 1988 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
Fresenius Medcl | DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER | calcium chloride; dextrose; magnesium chloride; sodium chloride; sodium lactate | SOLUTION;INTRAPERITONEAL | 020171-002 | Aug 19, 1992 | AT | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ||||
Fresenius Medcl | CALCITRIOL | calcitriol | INJECTABLE;INJECTION | 075766-001 | Feb 20, 2003 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Fresenius Medcl
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Fresenius Medcl | PHOSLO GELCAPS | calcium acetate | CAPSULE;ORAL | 021160-003 | Apr 2, 2001 | 6,576,665 | ⤷ Subscribe |
Fresenius Medcl | PHOSLO | calcium acetate | CAPSULE;ORAL | 021160-001 | Apr 2, 2001 | 4,870,105 | ⤷ Subscribe |
Fresenius Medcl | PHOSLO | calcium acetate | TABLET;ORAL | 019976-001 | Dec 10, 1990 | 4,870,105 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for FRESENIUS MEDCL drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Oral Solution | 667 mg/5 mL | ➤ Subscribe | 2013-12-05 |
➤ Subscribe | Capsules | EQ 169 mg calcium | ➤ Subscribe | 2005-05-31 |
International Patents for Fresenius Medcl Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
European Patent Office | 2484352 | ⤷ Subscribe |
South Korea | 101553719 | ⤷ Subscribe |
Poland | 2484352 | ⤷ Subscribe |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Fresenius Medcl Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0579826 | SPC/GB02/042 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: ERTAPENEM ((1R,5S,6S,8R,2'S,4'S)-2-(2-(3-CARBOXYPHENYLCARBAMOYL)PYRROLIDIN-4-YLTHIO)-6-(1-HYDROXYETHYL)-1-METHYLCARBAPENEM-3-CARBOXYLIC ACID), A PHARMACEUTICALLY ACCEPTABLE SALT OR IN VIVO HYDROLYSABLE ESTER THEREOF, ESPECIALLY AS THE MONOSODIUM SALT ERTA; REGISTERED: UK EU/1/02/216/001 20020422 |
2465580 | SPC/GB21/030 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: CABOTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING CABOTEGRAVIR SODIUM.; REGISTERED: UK EU/1/20/1481 (NI) 20201221; UK PLGB 35728/0055-57 20201221 |
2957286 | 6/2019 | Austria | ⤷ Subscribe | PRODUCT NAME: PATIROMER UND SEINE CALCIUM-SALZE; REGISTRATION NO/DATE: EU/1/17/1179 (MITTEILUNG) 20170721 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.